GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Chordate Medical Holding AB (OSTO:CMH) » Definitions » 5-Year RORE %

Chordate Medical Holding AB (OSTO:CMH) 5-Year RORE % : -44.11% (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Chordate Medical Holding AB 5-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Chordate Medical Holding AB's 5-Year RORE % for the quarter that ended in Dec. 2023 was -44.11%.

The industry rank for Chordate Medical Holding AB's 5-Year RORE % or its related term are showing as below:

OSTO:CMH's 5-Year RORE % is ranked worse than
86.85% of 654 companies
in the Medical Devices & Instruments industry
Industry Median: -1.27 vs OSTO:CMH: -44.11

Chordate Medical Holding AB 5-Year RORE % Historical Data

The historical data trend for Chordate Medical Holding AB's 5-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chordate Medical Holding AB 5-Year RORE % Chart

Chordate Medical Holding AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
5-Year RORE %
Get a 7-Day Free Trial Premium Member Only - 2.06 -47.24 -68.89 -44.11

Chordate Medical Holding AB Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
5-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -68.89 -63.59 -48.98 -48.10 -44.11

Competitive Comparison of Chordate Medical Holding AB's 5-Year RORE %

For the Medical Devices subindustry, Chordate Medical Holding AB's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chordate Medical Holding AB's 5-Year RORE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Chordate Medical Holding AB's 5-Year RORE % distribution charts can be found below:

* The bar in red indicates where Chordate Medical Holding AB's 5-Year RORE % falls into.



Chordate Medical Holding AB 5-Year RORE % Calculation

Chordate Medical Holding AB's 5-Year RORE % for the quarter that ended in Dec. 2023 is calculated as:

5-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 5-year -Cumulative Dividends per Share for 5-year )
=( -0.099--0.672 )/( -1.299-0 )
=0.573/-1.299
=-44.11 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2023 and 5-year before.


Chordate Medical Holding AB  (OSTO:CMH) 5-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Chordate Medical Holding AB 5-Year RORE % Related Terms

Thank you for viewing the detailed overview of Chordate Medical Holding AB's 5-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Chordate Medical Holding AB (OSTO:CMH) Business Description

Traded in Other Exchanges
Address
c/o Regus, Kistagangen 20B, Kista, SWE, 164 40
Chordate Medical Holding AB is a medical technology company that has developed and patented and CE-marked a new nerve-modulating treatment technology for chronic nasal congestion and chronic migraine. The company sells its products in Selected European markets, Israel and Saudi Arabia. The company's product range is based on the CE-marked treatment units Chordate System S100 and S120 for rhinitis and S220 for migraine, registered for the indications of preventive treatment of chronic migraine and chronic rhinitis and use on patients who are 18 years old or older. The company sells its product system, including treatments, through distributors to clinics and hospitals in its primary markets.

Chordate Medical Holding AB (OSTO:CMH) Headlines

No Headlines